The global market for antibody drugs was valued at $218.6 billion in 2023. The market is forecast to grow at a CAGR of 11.2% during the forecast period to reach $412.1 billion by the end of 2029. The increasing product approvals and growing prevalence of cancer and autoimmune diseases are driving the market’s growth. Price control pressures and the side effects of mAb therapies will challenge the market’s growth.
This report sections the global market by antibody type, manufacturing process type, application, and region. By antibody type, the market is categorized by human, humanized, chimeric, and murine. The human antibodies segment, which held the largest share in 2023, is expected to grow at a CAGR of 13.4% during the forecast period.
In terms of applications, the autoimmune diseases segment is forecast to grow at a CAGR of 10.6% during the forecast period. This segment accounted for 39.5% of the market in 2023 and is projected to reach a value of $158.5 billion by the end of 2029.
North America held the largest market share of 54.9% by region in 2023. The presence of large biopharmaceutical companies and an increasing number of product launches in the region are responsible for the large share.
The North American market for antibody drugs is expected to grow from $132.2 billion in 2024 and is projected to reach $215.9 billion by the end of 2029, at a CAGR of 10.3% during the forecast period of 2024 to 2029. The European market for antibody drugs is expected to grow from $71.6 billion in 2024 and is projected to reach $126.9 billion by the end of 2029, at a CAGR of 12.1% during the forecast period of 2024 to 2029.
Leading companies in the global market include F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., AbbVie Inc., Merck KGaA, and Amgen Inc.
Report Scope
This study offers a global view of the antibody drugs that have become key components of the pharmaceutical and biopharmaceutical markets. It analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when attached to cytotoxic agents such as antibody drug conjugates (ADCs).
The report analyzes and made projections of each market and its applications, along with an analysis of the regulatory environment, new products and technological advances. Also included in the report are profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., and Merck KGaA.
Monoclonal antibodies are finding growing use in the treatment of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review of their applications in various disease sectors. The overall market for antibody drug products includes four primary areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis and cardiovascular diseases.
This report excludes polyclonal antibodies, screening kits and diagnostic uses of mAbs. It also excludes the research applications of mAbs and therapeutic antibodies for veterinary use. The report excludes antibody products for COVID-19 and vaccine-based products.
The market is segmented by geographical region: North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Regional analysis is further broken down by country as follows: North America - the U.S., Canada and Mexico; Europe - Germany, the U.K., France, Italy, Spain, and the Rest of Europe; Asia-Pacific - China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2021 and 2022 as the historic years, 2023 as the base year, and forecasts through 2029.
The report includes:
- 76 data tables and 55 additional tables
- An updated review of the global market for antibody drugs
- Analyses of the global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
- Evaluation of the overall market for antibody drugs, and corresponding market share analysis by type, manufacturing process, application, and region
- Description of antibody functions and how they compare with antigens, and a discussion of monoclonal antibodies (mAbs), including their history, advantages and disadvantages, types, manufacturing technologies and applications
- Coverage of new approvals, recalls, safety alerts and clinical trials of mAbs, as well as technical issues related to human anti-mouse antibody (HAMA), and factors affecting mAB drugs
- An assessment of the major technologies for the formulation of antibody drugs and their relation to biotechnology, immunology, pharmaceuticals, and biodefense companies
- Discussions of the market dynamics, opportunities and challenges, as well as emerging technologies
- Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
- Competitive intelligence, including companies’ market shares, recent M&A activity and venture funding
- Profiles of the leading companies, including F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., AbbVie Inc., Merck KGaA, and Amgen Inc.
Table of Contents
Samples
LOADING...
Executive Summary
Antibody drugs are created through the use of modern scientific techniques such as genetic engineering and recombinant deoxyribonucleic acid (DNA) technology. They are produced by living cells and organisms such as Escherichia coli (E. coli), yeast, mammalian cells, etc. These protein drugs have gained in significance due to the increase in the number of chronic diseases such as asthma, multiple sclerosis and arthritis, and fatal diseases such as cancer and cardiovascular diseases. The antibody drug industry has grown globally due to its pivotal role in the treatment of life-threatening diseases. This report analyzes and assesses the therapeutic applications of antibodies such as mAbs in human medicine, including the combination of mAbs when they are attached to cytotoxic agents, such as antibody drug conjugates.
Genetic engineering technology has made it possible to produce these protein molecules with modified features. Owing to its high specificity and low immunogenicity, protein therapeutics is widely used to treat various life-threatening diseases such as cancer, diabetes and multiple sclerosis. Increasing R&D, increasingly sedentary lifestyles, increasing incidence of various diseases and the growing population of baby-boomers are the driving forces for the monoclonal antibody market.
Leading manufacturers of mAbs include F. Hoffmann-La Roche Ltd., Johnson & Johnson Inc., Novartis AG, Biogen Inc., Amgen Inc., Merck & Co. and AbbVie Inc. Novel antibody drugs increasingly are being investigated and developed due to advances in technology. Approaches such as the development of antibody drug conjugates and bi-specific antibodies that attack the proteins present inside a cancerous cell are the present-day outlook of R&D of therapies. These therapies suppress the further progression of diseases such as arthritis, multiple sclerosis, hepatitis, Crohn’s disease, acquired immunodeficiency syndrome (AIDS), etc.
Human monoclonal antibodies (mAbs) are the largest segment in terms of revenue, followed by other mAb categories such as humanized, chimeric and murine. The use of mAbs in therapeutics such as oncology, autoimmune and inflammatory diseases should increase during the forecast period, although this market is likely to face competition from the entry of follow-on-biologics and biosimilars.The market increase also stems from the industry’s strong pipeline with many late-stage developmentmolecules.
The U.S. leads the antibody drugs market. Follow-on-biologics and price pressures are the major threats for the market. A rapid increase in medical technologies, improved diagnosis of disease and the expansion of healthcare in emerging markets are expected to positively impact the market. Also, the impact of COVID-19 has boosted growth in the antibody market as many monoclonal antibodies have granted emergency use authorization and approval for the treatment of COVID-19.
The market for antibody drugs is divided into four types of diseases: autoimmune diseases, solid tumors, lymphoma, leukemia and multiple myeloma, and other diseases such as asthma, osteoporosis, cardiovascular diseases and others. In 2020, the largest Shares of the antibody drug market belonged to oncology (solid and hematological malignancies).
Companies Mentioned
- Abbvie Inc.
- Alexion Pharmaceuticals
- Amgen Inc.
- AstraZeneca Pharmaceuticals
- Biogen
- Bristol-Myers Squibb Co
- Eli Lilly
- F. Hoffmann-La Roche Ag
- Fresenius Kabi
- Genmab A/S
- Gilead Sciences Inc.
- Glaxosmithkline
- Johnson & Johnson
- Merck & Co. Inc.
- Merck Kgaa
- Novartis Ag
- Pfizer Inc.
- Regeneron Pharmaceuticals
- Sanofi S.A.
- Seagen
- Takeda Pharmaceutical Co., Ltd.
- UCB Co.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 156 |
| Published | September 2024 |
| Forecast Period | 2024 - 2029 |
| Estimated Market Value ( USD | $ 242.6 Billion |
| Forecasted Market Value ( USD | $ 412.1 Billion |
| Compound Annual Growth Rate | 11.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
